Latest article
Robert W. Baird Keep on with Their Maintain Ranking for Tandem Diabetes Care By...
Jeff Johnson, an analyst at Robert W. Baird, on Thursday maintained a hold rating for Tandem Diabetes Care (NASDAQ :) and set a price...
U.S. FDA declines to approve Provention Bio’s diabetes drug
(Reuters) - The U.S. Food and Drug Administration on Tuesday rejected Prevention Bio Inc.'s approval of the experimental diabetes drug teplizumab, citing insufficient data,...